Page 78 - e-book CPG - Bipolar Disorder

CLINICAL PRACTICE GUIDELINES MANAGEMENT OF BIPOLAR DISORDER (2ND ED.)

therapeutic the below and growth in younger, in not is levels be therapeutic monitored should the not have serum levels that are affect adversely to therapeutic the below younger, in in not levels younger, is not is levels affect advers

POSSIBLE AND COMPATIBLE TO USE IN LACTATION. dosage might also be advisable. to adversely affect infant growth or development. POSSIBLE TO USE CAUTIOUSLY IN LACTATION. but measurable, months of age and during lithium monotherapy. no indicate developmental LACTATION POSSIBLE AND COMPATIBLE TO U

LACTATION LACTATION Monitoring of infant’s platelet count, liver function and serum concentrations before and after increases in maternal lamotrigine Breastfeeding during carbamazepine monotherapy does not appear **RID: 5 - 31%. and its active metabolite have relatively high levels in breastmilk

 o   Carbamazepine   sometimes  range.  reported.  Monitoring:  data limited Monitor inf o and   elimination is  Measuring o     in breastmilk and AEs are observed. during sometimes   range. Lamotrigine   
BIPOLAR and malformations and BIPOLAR BIPOLAR the in and malformations and malformations and and pregnancy. during 64 early in 63 pregnancy. during pregnancy. during 63 63

OF malformations increased risk of cardiac hypoplasia OF OF toxicity malformations malformations hypoplasia hypoplasia to prior monthly to to prior monthly to to prior monthly to
TREATMENT congenital fingernail TREATMENT TREATMENT severe produce congenital fingernail fingernail twice up twice up twice up

PREGNANCY PREGNANCY FOR Carbamazepine and its active metabolite cross the placenta; May be associated with teratogenic effects, including spina bifida, cardiovascular Foetal echocardiography between 16 and 20 weeks gestation of Risk should be considered in a woman with first-trim

RECOMMENDED concentrations are variable. HUMAN DATA SUGGEST RISK. defects, delays. increases with higher doses. exposure because of the potential craniofacial developmental delay. RECOMMENDED RECOMMENDED concentrations are variable. near drug defects, concentrations are variable.

NOT DISORDER. craniofacial developmental malformations. . minor of pregnancy. NOT DISORDER. NOT DISORDER. Use Carbam craniofacial developmental RISK craniofacial developmental minor of minor doses. of Monitoring: o should RISK Monitoring partu
                                   

MEDICATION MEDICATION Carbamazepine Lithium MEDICATION Carbamazepine MEDICATION Carbamazepine Lamotrigine Lamotrigine Lamotrigine

MOOD STABILISERS MOOD STABILISERS MOOD STABILISERS

64